139 related articles for article (PubMed ID: 33628103)
1. LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells.
Ma Y; Xu R; Liu X; Zhang Y; Song L; Cai S; Zhou S; Xie Y; Li A; Cao W; Tang X
Int J Med Sci; 2021; 18(6):1456-1464. PubMed ID: 33628103
[No Abstract] [Full Text] [Related]
2. Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways.
Üremiş MM; Üremiş N; Türköz Y
Steroids; 2023 Oct; 198():109261. PubMed ID: 37355001
[TBL] [Abstract][Full Text] [Related]
3. Dietary antioxidant quercetin overcomes the acquired resistance of Sorafenib in Sorafenib-resistant hepatocellular carcinoma cells through epidermal growth factor receptor signaling inactivation.
Zhang Z; Wu H; Zhang Y; Shen C; Zhou F
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):559-574. PubMed ID: 37490119
[TBL] [Abstract][Full Text] [Related]
4. 3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy.
Zhao F; Feng G; Zhu J; Su Z; Guo R; Liu J; Zhang H; Zhai Y
Anticancer Drugs; 2021 Apr; 32(4):386-393. PubMed ID: 33395067
[TBL] [Abstract][Full Text] [Related]
5. EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy.
Xia H; Dai X; Yu H; Zhou S; Fan Z; Wei G; Tang Q; Gong Q; Bi F
Cell Death Dis; 2018 Feb; 9(3):269. PubMed ID: 29449645
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells.
Osawa M; Matsuda Y; Kinoshita Y; Wakai T
Anticancer Res; 2021 Feb; 41(2):645-660. PubMed ID: 33517269
[TBL] [Abstract][Full Text] [Related]
7. Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma.
Hu Y; Luo Z; Cai S; Xie Q; Zheng S
Scand J Gastroenterol; 2024 Jun; 59(6):730-736. PubMed ID: 38426342
[TBL] [Abstract][Full Text] [Related]
8. β-HB treatment reverses sorafenib resistance by shifting glycolysis-lactate metabolism in HCC.
Suk FM; Wu CY; Fang CC; Chen TL; Liao YJ
Biomed Pharmacother; 2023 Oct; 166():115293. PubMed ID: 37567069
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma.
Kim Y; Jung KY; Kim YH; Xu P; Kang BE; Jo Y; Pandit N; Kwon J; Gariani K; Gariani J; Lee J; Verbeek J; Nam S; Bae SJ; Ha KT; Yi HS; Shong M; Kim KH; Kim D; Jung HJ; Lee CW; Kim KR; Schoonjans K; Auwerx J; Ryu D
Drug Resist Updat; 2024 Mar; 73():101054. PubMed ID: 38277756
[TBL] [Abstract][Full Text] [Related]
10. ATRA sensitized the response of hepatocellular carcinoma to Sorafenib by downregulation of p21-activated kinase 1.
Wang K; Qiu X; Zhang Z; Xu H; Tan Y; Su R; Gao F; Zhuo J; Li W; Lian Z; He H; Xu X
Cell Commun Signal; 2023 Aug; 21(1):193. PubMed ID: 37537668
[TBL] [Abstract][Full Text] [Related]
11. Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro.
Dituri F; Scialpi R; Schmidt TA; Frusciante M; Mancarella S; Lupo LG; Villa E; Giannelli G
Cell Death Dis; 2020 Nov; 11(11):984. PubMed ID: 33199679
[TBL] [Abstract][Full Text] [Related]
12. eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma.
Fang C; Xie H; Zhao J; Wang W; Hou H; Zhang B; Zhou D; Geng X
Anticancer Drugs; 2021 Sep; 32(8):822-828. PubMed ID: 33783376
[TBL] [Abstract][Full Text] [Related]
13. Modelling the Sorafenib-resistant Liver Cancer Microenvironment by Using 3-D Spheroids.
Sariyar E; Firtina Karagonlar Z
Altern Lab Anim; 2023 Sep; 51(5):301-312. PubMed ID: 37555318
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1.
Zhao J; Lin E; Bai Z; Jia Y; Wang B; Dai Y; Zhuo W; Zeng G; Liu X; Cai C; Li P; Zou B; Li J
BMC Cancer; 2023 Dec; 23(1):1198. PubMed ID: 38057830
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma.
Dong R; Wang T; Dong W; Zhu H; Liu Q; Liang H; Chen X; Zhang B; Zhang X
Biomed Pharmacother; 2024 Apr; 173():116366. PubMed ID: 38458013
[TBL] [Abstract][Full Text] [Related]
16. Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach.
Ng WH; Soo KC; Huynh H
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338842
[TBL] [Abstract][Full Text] [Related]
17. Time Course of Changes in Sorafenib-Treated Hepatocellular Carcinoma Cells Suggests Involvement of Phospho-Regulated Signaling in Ferroptosis Induction.
Werth EG; Rajbhandari P; Stockwell BR; Brown LM
Proteomics; 2020 May; 20(10):e2000006. PubMed ID: 32336023
[TBL] [Abstract][Full Text] [Related]
18. Studying the Role and Molecular Mechanisms of
Shi Y; Mo X; Hong S; Li T; Chen B; Chen G
Biomed Res Int; 2020; 2020():4965670. PubMed ID: 33204699
[TBL] [Abstract][Full Text] [Related]
19. Aldehyde Dehydrogenase 2 (ALDH2): A novel sorafenib target in hepatocellular carcinoma unraveled by the proteome-wide cellular thermal shift assay.
Ferreira IC; Torrejón E; Abecasis B; Alexandre BM; Gomes RA; Verslype C; van Pelt J; Barbas A; Simão D; Bandeiras TM; Bortoluzzi A; Rebelo SP
SLAS Discov; 2024 Apr; 29(3):100154. PubMed ID: 38521503
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of HCG18 in the sorafenib resistance of hepatocellular carcinoma.
Li H; Hu J; Qiu L; Wu Y; Zhong B; Ye R; Xie B
Anticancer Drugs; 2024 Jan; 35(1):55-62. PubMed ID: 37823256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
